观察顺铂及因特康对癌性胸水的疗效和副反应。方法：对癌性胸水患者分别用顺铂或因特康胸腔内灌注。结果：用顺铂治疗组ＣＲ２９．４％，ＰＲ２３．５％，消化道反应５８．８％，造血系统反应４７．１％。因特康治疗ＣＲ３３．３％，ＰＲ２６．７％，无消化道及造血系统反应。结论：顺铂与因特康治疗癌性胸水总有效率分别为５２．９％和６０．０％，二者无显著性差异，但顺铂组白细胞下降及消化系统反应较重，应慎用 Observe the efficacy and side effects of cisplatin and Intcon on cancerous pleural effusion. Methods: Patients with cancerous pleural effusion were treated with cisplatin or intracancer intrapleural infusion, respectively. RESULTS: In the cisplatin treatment group, CR was 29.4%, PR was 23.5%, digestive tract reaction was 58.8%, and hematopoietic system reaction was 47.1%. Intecom treatment CR33.3%, PR26.7%, no gastrointestinal and hematopoietic system reactions. CONCLUSIONS: The total effective rates of cisplatin and Intecan in treating cancerous pleural effusions were 52.9% and 60.0%, respectively. There was no significant difference between the two groups. However, the decline in white blood cells and the digestive system response in the cisplatin group was severe and should be used with caution.